EyePoint Pharmaceuticals, Inc. — Director's Dealing 2022

Jan 14, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2022-01-10

Reporting Person: Pine Michael Craig (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-01-10	Stock Option (Right to Buy)	$12.62	A	100000.00	Acquired	2032-01-10	Common Stock (100000.00)	Direct

Footnotes

F1: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months